trial

Melatonin for Prevention of Metabolic Side Effects of Olanzapine

NCTId NCT01593774
as of 2026-07-01
at a glance
Phase 2 · Completed
Enrollment 36 (actual)
Primary completion 2013-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
36 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2012-05
Primary completion
2013-03
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Sponsors

Investigators

1

Sites

1 total
Rasht, Iran

Linked catalysts

1

Facts & assertions

4 sourced
Enrollment
36
Phase
PHASE2
Primary Completion Date
2013-03
Status
COMPLETED
relationships
The graph out of here
drug
indication